

Eric Delabesse

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2839462/eric-delabesse-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149
papers

14,004
citations

41
h-index

118
g-index

157
ext. papers

15,658
ext. citations

5.7
avg, IF

5
L-index

#	Paper	IF	Citations
149	LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. <i>Science</i> , 2003 , 302, 415-9	33.3	2822
148	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2003 , 17, 2257-317	10.7	2404
147	Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3132-42	15.9	1269
146	Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using Real-time quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. <i>Leukemia</i> , 2003 , 17, 2474-86	10.7	717
145	Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. <i>Lancet, The</i> , 2000 , 356, 203-8	40	576
144	Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 911-8	2.2	411
143	Abnormal intestinal intraepithelial lymphocytes in refractory sprue. <i>Gastroenterology</i> , 1998 , 114, 471-81	13.3	311
142	Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R β -deficient mice. <i>Journal of Clinical Investigation</i> , 2011 , 121, 384-95	15.9	277
141	Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. <i>Blood</i> , 2007 , 109, 1408-13	2.2	260
140	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 2213-23	2.2	248
139	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009 , 114, 3285-91	2.2	231
138	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014 , 123, 3739-49	2.2	225
137	A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). <i>Nature Genetics</i> , 2011 , 43, 673-8	36.3	218
136	Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2225-32	15.9	197
135	Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. <i>EMBO Journal</i> , 2002 , 21, 3039-50	13	184
134	The MLL recombinome of acute leukemias. <i>Leukemia</i> , 2006 , 20, 777-84	10.7	175
133	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 822-9	2.2	160

132	Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. <i>Leukemia</i> , 2002 , 16, 587-93	10.7	132
131	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 125, 13-21	2.2	129
130	Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. <i>Blood</i> , 2003 , 101, 2693-703	2.2	128
129	CALM-AF10 is a common fusion transcript in T-ALL and is specific to the TCRgammadelta lineage. <i>Blood</i> , 2003 , 102, 1000-6	2.2	127
128	High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. <i>Haematologica</i> , 2011 , 96, 1792-8	6.6	125
127	Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. <i>Cancer Cell</i> , 2006 , 10, 363-74	24.3	114
126	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2007 , 109, 2202-4	2.2	103
125	CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. <i>Leukemia</i> , 2005 , 19, 1948-57	10.7	100
124	Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. <i>Leukemia</i> , 2006 , 20, 1526-32	10.7	89
123	FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. <i>Blood</i> , 2003 , 102, 2198-204	2.2	85
122	Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. <i>Blood</i> , 2004 , 104, 4173-80	2.2	85
121	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. <i>Blood</i> , 2016 , 127, 882-92	2.2	81
120	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. <i>Haematologica</i> , 2018 , 103, 1278-1287	6.6	74
119	Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 2618-26	2.2	74
118	TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. <i>PLoS ONE</i> , 2012 , 7, e31605	3.7	66
117	Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. <i>Blood</i> , 2002 , 99, 4547-53	2.2	64
116	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2514-2523	2.2	57
115	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016 , 213, 483-97	16.6	54

114	Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo. <i>Molecular and Cellular Biology</i> , 2005 , 25, 5215-25	4.8	53
113	Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. <i>Oncotarget</i> , 2015 , 6, 8388-96	3.3	52
112	CHK1 as a therapeutic target to bypass chemoresistance in AML. <i>Science Signaling</i> , 2016 , 9, ra90	8.8	49
111	The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. <i>Blood</i> , 2000 , 96, 2254-2261	2.2	49
110	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2017 , 130, 1832-1844	2.2	44
109	Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL?. <i>Leukemia</i> , 2002 , 16, 2134-41	10.7	42
108	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013 , 98, 1748-52	6.6	40
107	DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. <i>Leukemia</i> , 2005 , 19, 1338-44	10.7	40
106	Improved outcome for AML patients over the years 2000-2014. <i>Blood Cancer Journal</i> , 2017 , 7, 635	7	39
105	Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network. <i>American Journal of Hematology</i> , 2014 , 89, E244-52	7.1	37
104	Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2013 , 98, 1414-20	6.6	37
103	Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele. <i>Leukemia</i> , 2007 , 21, 1232-8	10.7	37
102	Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2364-73	6.1	36
101	Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. <i>Blood</i> , 2011 , 117, 5719-22	2.2	35
100	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. <i>Haematologica</i> , 2015 , 100, 780-5	6.6	34
99	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. <i>Haematologica</i> , 2013 , 98, 1711-7	6.6	33
98	Simultaneous SIL-TAL1 RT-PCR detection of all tal(d) deletions and identification of novel tal(d) variants. <i>British Journal of Haematology</i> , 1997 , 99, 901-7	4.5	32
97	Dexamethasone in hyperleukocytic acute myeloid leukemia. <i>Haematologica</i> , 2018 , 103, 988-998	6.6	31

96	Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2017 , 1, 1760-1772	7.8	30
95	Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17). <i>Blood</i> , 2006 , 108, 3484-93	2.2	30
94	Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies. <i>British Journal of Haematology</i> , 2004 , 127, 509-18	4.5	30
93	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019 , 102, 131-142	3.8	30
92	PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. <i>Leukemia Research</i> , 2012 , 36, 1365-9	2.7	26
91	TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. <i>Haematologica</i> , 2011 , 96, 1059-63	6.6	26
90	Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. <i>Oncotarget</i> , 2011 , 2, 850-61	3.3	26
89	HOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocation. <i>Leukemia</i> , 2006 , 20, 1184-7	10.7	25
88	Mono/oligoclonal pattern of Kaposi Sarcoma-associated herpesvirus (KSHV/HHV-8) episomes in primary effusion lymphoma cells. <i>International Journal of Cancer</i> , 2005 , 115, 511-8	7.5	25
87	Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses. <i>Leukemia and Lymphoma</i> , 2000 , 38, 401-9	1.9	25
86	Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. <i>PLoS ONE</i> , 2010 , 5, e8893	3.7	25
85	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016 , 7, 73769-73780	3.3	25
84	Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. <i>Haematologica</i> , 2017 , 102, 1718-1726	6.6	24
83	Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2017 , 35, 664-670	1.3	24
82	P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019 , 133, 280-284	2.2	24
81	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. <i>Haematologica</i> , 2014 , 99, e185-7	6.6	23
80	Epidermal growth factor receptor/beta-catenin/T-cell factor 4/matrix metalloproteinase 1: a new pathway for regulating keratinocyte invasiveness after UVA irradiation. <i>Cancer Research</i> , 2009 , 69, 3291-9	10.1	22
79	Primary cutaneous Epstein-Barr virus-related lymphoproliferative disorders in 4 immunosuppressed children. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 74-80	4.5	21

78	Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. <i>Leukemia Research</i> , 2017 , 61, 62-67	2.7	20
77	Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1998 , 23, 220-226	5	18
76	Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy. <i>American Journal of Hematology</i> , 2016 , 91, 193-8	7.1	18
75	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3203-3210	2.2	18
74	Primary leptomenigeal ALK+ lymphoma in a 13-year-old child. <i>Journal of Pediatric Hematology/Oncology</i> , 2008 , 30, 963-7	1.2	17
73	Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Leukemia</i> , 2006 , 20, 793-9	10.7	17
72	Is Complicated Celiac Disease or Refractory Sprue an Intestinal Intra-Epithelial Cryptic T-Cell Lymphoma?. <i>Blood</i> , 1999 , 93, 3154-3155	2.2	17
71	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020 , 136, 698-714	2.2	16
70	Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. <i>British Journal of Haematology</i> , 2012 , 159, 599-602	4.5	16
69	Association of a duodenal follicular lymphoma and hereditary nonpolyposis colorectal cancer. <i>Modern Pathology</i> , 2000 , 13, 586-90	9.8	16
68	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. <i>Oncotarget</i> , 2015 , 6, 38061-78	3.3	16
67	TAL1 expression does not occur in the majority of T-ALL blasts. <i>British Journal of Haematology</i> , 1998 , 102, 449-57	4.5	15
66	AF4p12, a human homologue to the furry gene of Drosophila, as a novel MLL fusion partner. <i>Cancer Research</i> , 2005 , 65, 6521-5	10.1	15
65	IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner. <i>Leukemia</i> , 2005 , 19, 2337-8	10.7	14
64	B-ALL With t(5;14)(q31;q32); Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar -Rearranged B-ALL. <i>Frontiers in Oncology</i> , 2019 , 9, 1374	5.3	12
63	Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. <i>European Journal of Haematology</i> , 2014 , 93, 533-6	3.8	11
62	Deregulated expression of the TAL1 gene by t(1;5)(p32;31) in patient with T-cell acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 1998 , 23, 36-43	5	11
61	Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2021 , 137, 1424-1428	2.2	11

60	PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 10357-10362	11.5	10
59	Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience. <i>Cancer Medicine</i> , 2019 , 8, 3846-3854	4.8	9
58	A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device. <i>Cancer Genetics and Cytogenetics</i> , 2007 , 173, 17-22		9
57	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016 , 128, 762-762	2.2	9
56	Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. <i>Leukemia Research</i> , 2019 , 81, 82-87	2.7	8
55	Comparison of 60 or 90 mg/m ² of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. <i>American Journal of Hematology</i> , 2015 , 90, E29-30	7.1	8
54	Transcriptional activation of the cardiac homeobox gene CSX1/NKX2-5 in a B-cell chronic lymphoproliferative disorder. <i>Haematologica</i> , 2008 , 93, 1081-5	6.6	7
53	Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience. <i>Leukemia</i> , 2006 , 20, 2178-81	10.7	7
52	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. <i>Leukemia</i> , 2021 ,	10.7	7
51	Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.. <i>Blood</i> , 2004 , 104, 2741-2741	2.2	6
50	Long-Term Results of the Imatinib GRAAPH-2003 Study in Newly-Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia... <i>Blood</i> , 2009 , 114, 3080-3080	2.2	6
49	Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. <i>Cancer Genetics and Cytogenetics</i> , 2006 , 169, 174-5		5
48	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. <i>Clinical Cancer Research</i> , 2020 , 26, 3307-3318	12.9	5
47	A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study. <i>Clinical Biochemistry</i> , 2015 , 48, 982-7	3.5	4
46	CD34CD38CD123 Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. <i>Cancers</i> , 2020 , 12,	6.6	4
45	Outcome of Relapsed or Refractory -Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020 , 12,	6.6	4
44	Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9. <i>Genes Chromosomes and Cancer</i> , 2006 , 45, 575-82	5	4
43	Efficacy of Frontline 5-Azacytidine in Older AML Patient Unfit for Chemotherapy. <i>Blood</i> , 2011 , 118, 2614-2614	4	4

42	Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. <i>Blood Advances</i> , 2020 , 4, 3840-3849	7.8	4
41	More than ten percent of relapses occur after five years in AML patients with mutation. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1226-1229	1.9	3
40	A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2489-2492	1.9	3
39	Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia. <i>Leukemia</i> , 2018 , 32, 2066-2069	10.7	3
38	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. <i>Blood</i> , 2011 , 118, 2535-2535	2.2	3
37	The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations. <i>Blood</i> , 2015 , 126, 2542-2542	2.2	3
36	Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. <i>PLoS ONE</i> , 2020 , 15, e0238795	3.7	3
35	Real-World Outcomes of Patients with Refractory or Relapsed -ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. <i>Cancers</i> , 2020 , 12,	6.6	3
34	The impact of chronic myeloid leukemia on employment: the French prospective study. <i>Annals of Hematology</i> , 2019 , 98, 615-623	3	3
33	and isoforms are both efficient to drive B cell differentiation. <i>Oncotarget</i> , 2018 , 9, 32841-32854	3.3	3
32	Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. <i>Leukemia Research</i> , 2010 , 34, e88-90	2.7	2
31	Detection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assay. <i>Human Pathology</i> , 2007 , 38, 1581-2	3.7	2
30	Prognostic Significance of CD20 Expression in Adult B-Cell Precursor Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007 , 110, 2829-2829	2.2	2
29	Cytosine Arabinoside Chemotherapy Does Not Enrich For Leukemic Stem Cells In Xenotransplantation Model Of Human Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1651-1651	2.2	2
28	Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial. <i>European Journal of Haematology</i> , 2021 , 107, 111-121	3.8	2
27	The CALM-AF10 fusion is a rare event in acute megakaryoblastic leukemia. <i>Leukemia</i> , 2007 , 21, 2568-9	10.7	1
26	Number of Mutations and Type of Prior Myeloproliferative Neoplasm Are Prognostic Factors in Acute Myeloid Leukemia Post Myeloproliferative Neoplasms. <i>Blood</i> , 2018 , 132, 2806-2806	2.2	1
25	PAX5 Mutations Occur Frequently in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Is Significantly Associated with BCR-ABL1 Fusion Gene.. <i>Blood</i> , 2007 , 110, 2806-2806	2.2	1

24	Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. <i>Blood</i> , 2013 , 122, 2681-2681	2.2	1
23	Outcome of AML Patients with IDH1 or IDH2 Mutations from Diagnosis and Refractory/Relapse Phase of the Disease in Routine Practice. <i>Blood</i> , 2016 , 128, 1718-1718	2.2	1
22	Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2016 , 128, 2892-2892	2.2	1
21	Genomic landscape of hyperleukocytic acute myeloid leukemia.. <i>Blood Cancer Journal</i> , 2022 , 12, 4	7	1
20	GATA2 deficiency phenotype associated with tandem duplication GATA2 and over-expression of GATA2-AS1. <i>Blood Advances</i> , 2021 ,	7.8	1
19	Outcome of relapsed/refractory AML patients with IDH1 mutations in real life before the era of IDH1 inhibitors. <i>Leukemia and Lymphoma</i> , 2020 , 61, 473-476	1.9	1
18	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021 , 35, 1291-1300	10.7	1
17	Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis. <i>Leukemia Research</i> , 2018 , 75, 7-10	2.7	1
16	GATA2, a new oncogene of sporadic and familial acute myeloid leukemias. <i>Hematologie</i> , 2014 , 20, 153-160		
15	Application de l'hématologie maligne des techniques de biologie moléculaire. <i>EMC Hématologie</i> , 2006 , 1, 1-14		
14	Absence of SCL mutations in myeloid malignancies. <i>British Journal of Haematology</i> , 2003 , 120, 482-3	4.5	
13	Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study. <i>Leukemia and Lymphoma</i> , 1-9	1.9	
12	Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 180	7	
11	Novel Spliced MLL Fusions Have Been Identified Involving the MLL Partner Genes ELL, EPS15, MLLT3, and SEPT5.. <i>Blood</i> , 2007 , 110, 978-978	2.2	
10	Exome Sequencing Identifies Mecom Missense Variant As Prognostic Marker for Overall Survival of Elderly Acute Myeloid Patients Treated with Azacitidine. <i>Blood</i> , 2018 , 132, 1467-1467	2.2	
9	More Than 10% of NPM1-Mutated AML Relapses Occur after 5 Years from Complete Remission. <i>Blood</i> , 2018 , 132, 2802-2802	2.2	
8	TP53 Mutations Negatively Impact Survival of Acute Myeloid Leukemia Patients Treated with Standard Doses of Azacitidine. <i>Blood</i> , 2018 , 132, 2745-2745	2.2	
7	Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML. <i>Blood</i> , 2015 , 126, 90-90	2.2	

- 6 Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases. *Blood*, **2016**, 128, 2861-2861 2.2
- 5 Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia. *Blood*, **2016**, 128, 1636-1636 2.2
- 4 What Is New? An Update of the MLL Recombinome Including the Three Novel Partner Genes ABI2, PDS5A, and TOP3A. *Blood*, **2011**, 118, 1351-1351 2.2
- 3 Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial. *Blood*, **2011**, 118, 410-410 2.2
- 2 Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.. *Blood*, **2012**, 120, 2879-2879 2.2
- 1 T315I-Mutated BCR-ABL Induces a Distinct and Specific Molecular Signature With High Expression Of Zinc Finger (ZNF) Transcription Factors. *Blood*, **2013**, 122, 4899-4899 2.2